Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Cardiology

Journal Scan / Research · December 05, 2024

Effects of Zerlasiran on Lipoprotein(a) Serum Concentrations

JAMA: The Journal of the American Medical Association

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA: The Journal of the American Medical Association
Zerlasiran-A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial
JAMA 2024 Nov 18;[EPub Ahead of Print], SE Nissen, Q Wang, SJ Nicholls, AM Navar, KK Ray, GG Schwartz, M Szarek, ESG Stroes, R Troquay, JAN Dorresteijn, H Fok, DA Rider, S Romano, K Wolski, C Rambaran

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading